* Directors / Signatories / KMP / Principals

WOCKHARDT LIMITED

Company Status: Active As on: 06-Aug-2019

D&B Summary

Paid-up Capital(INR)
3,853,525,015
Authorised Capital(INR)
11,250,000,000
Total Charges(INR)
Open Charges(INR)
D&B Reports
Quick Check Report
INR 2500.00 /-
Report Status : Available
Financial Year : 2020
Basic Report
INR 6000.00 /-
Report Status : Available
Financial Year : 2020
Compliance Report
INR 14000.00 /-
Report Status : Available
Financial Year : 2020
Sectoral Risk Outlook (Industry Report)
Sectoral Risk Outlook (Industry Report) Status : Unavailable
Financial Year : NA
Business of interest
Low High
No. of search on company
40
80% Complete
News

Lipid Disorder Treatment Market by Type, Application and Forecast 2020 – 2027 | Key Players – Sun Pharmaceuticals, Wockhardt Limited. – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper


Wockhardt reports PAT at Rs 15 crore in Q3 - Medical Dialogues


Glucose Sensors Market to Gain Significant Revenue in the Period of 2026 – KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper


Skin and Soft Tissue Infection Treatment Market Size 2021 | Driving Factors by Manufacturers – Merck, Durata Therapeutics (Teva), Wockhardt Limited, Takeda Pharmaceutical, Atox Bio Inc. - Express Keeper


UK Government announces Covid-19 vaccination contract extension with Wockhardt - Indiainfoline


Comprehensive Report on Lipid Disorder Treatment Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 | Teva Pharmaceuticals, Mylan Pharmaceuticals, Kowa Pharmaceuticals, Glenmark Pharmaceuticals - NeighborWebSJ


Wockhardt : Man arrested over package sent to vaccine plant in Wales - marketscreener.com


Diabetes Pen Market Set to Register healthy CAGR Forecast to 2026 – The Courier - The Courier


Skin and Soft Tissue Infection Treatment Market is booming worldwide with Forecast Period 2021-2027 by Key Players: Merck, Durata Therapeutics (Teva), Wockhardt Limited, Takeda Pharmaceutical - The Courier


Insulin Biosimilars Market Opportunities and Threats faced by the Key Vendors 2027 - The Courier


Lipid Disorder Treatment Market Size and Forecast (2021-2027) | By Top Leading Players – Mylan Pharmaceuticals, Teva Pharmaceuticals, Kowa Pharmaceuticals, Glenmark Pharmaceuticals, Sun Pharmaceuticals, Wockhardt Limited. - The Bisouv Network


Increasing Awareness About New Skin Care Treatments is Pushing Growth of Necrotizing Skin Infections Treatment Market to Newer Heights, Finds Fact.MR - BioSpace


Global Lipid Disorder Treatment Market To Experience A Stupendous Growth By 2026 - The Courier


Comprehensive Report on Human Insulin Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | B. Braun Melsungen AG, Becton, Dickinson and Company, Eli Lilly and Company - NeighborWebSJ


Global Lipid Disorder Treatment Market Status Analysis, Scope, Trend, Capacity and Forecast 2020-2025 – The Courier - The Courier


Skin and Soft Tissue Infection Treatment Market Size, Growth And Key Players- Merck, Durata Therapeutics (Teva), Wockhardt Limited, Takeda Pharmaceutical, Atox Bio Inc. – Express Keeper - Express Keeper


Antidiabetic Drug Market Research Report by Type, by Disease, by Patient - Global Forecast to 2025 - Cumulative Impact of COVID-19 - GlobeNewswire


Global Erythropoietin Stimulating Agents Industry Market 2021 Industry Size, Analysis, Growth, Opportunity & Forecast 2027:Serum Institute of India, Johnson & Johnson, Biocon, Celltrion, Inc., Teva Pharmaceutical Industries Ltd., Celon Labs - Express Keeper


Here's What We Learned About The CEO Pay At Wockhardt Limited (NSE:WOCKPHARMA) - Simply Wall St


Wockhardt Limited announces Q1FY21 earnings - Equity Bulls


Global Parkinson's Disease Treatment Market Evaluation of Recent Industry Developments For 2016-2024 – The Courier - The Courier


US Markets – Lipid Disorder Treatment Industry Market with (Covid-19) Impact Analysis: Worldwide Key Industry Segments & Forecast, 2021-2027 - NY Market Reports


Pharmaceutical Fill and Finish Outsourcing 2021 Global Market Study, Forecast to 2027 Focus on long-term growth Factors, Economic Recovery Analysis By Abbott Laboratories, Teva Pharmaceuticals Industries Ltd, Piramal Enterprises Ltd. - The Courier


Lipid Disorder Treatment Market Size, Share, Trends, Competitive Landscape and Forecast to 2027 – NeighborWebSJ - NeighborWebSJ


Lipid Disorder Treatment Market – Massive Growth opportunity Ahead | Teva Pharmaceuticals, Mylan Pharmaceuticals, Kowa Pharmaceuticals, Glenmark Pharmaceuticals - Express Keeper


LIVE: Bomb squad called to incident on Wrexham industrial estate where Covid jabs made - Cheshire Live


Lipid Disorder Treatment Market Growth And Status Explored In A New Research By 2027 – NeighborWebSJ - NeighborWebSJ


How Many Wockhardt Limited (NSE:WOCKPHARMA) Shares Do Institutions Own? - Simply Wall St


Global Parkinson's Disease Treatment Market SWOT Analysis, Key Indicators – The Bisouv Network - The Bisouv Network


Human Insulin Market Size 2021 | Business Status, Industry Trends and Forecast to 2027 – Express Keeper - Express Keeper


Global Skin and Soft Tissue Infection Treatment Market Outlook Industry Analysis, Size, Share, Growth, Trends and Forecast, 2027 - NY Market Reports


Dr. Reddy's Laboratories Completes the Acquisition of Select Business Divisions of Wockhardt - BioSpace


Wockhardt Preps To Deliver 100M Doses Of AZ Vaccine - Scrip


Erythropoietin Stimulating Agents Solutions Market to Witness Growth Acceleration During 2021-2025- Hospira Inc., Intas Pharmaceuticals, Biosidus, LG Life Sciences Ltd., Ranbaxy Laboratories Ltd - NeighborWebSJ


What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year? - Simply Wall St


Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA) - Simply Wall St


Wockhardt Jumps 48.2% In 8 Days; Heres Why You Should Stay Away From The Stock - Goodreturns


Global Human Insulin Market- Industry Analysis and Forecast (2020-2027) – By Application, Type, Distribution Channel, Brand, Drug Delivery Devices and Region. – Express Keeper - Express Keeper


Does Wockhardt (NSE:WOCKPHARMA) Have A Healthy Balance Sheet? - Simply Wall St


Dr. Reddy's Laboratories to Acquire Select Business Divisions of Wockhardt in India - Business Wire


Why You Should Not Buy Wockhardt Limited (NSE:WOCKPHARMA) For Dividend - Simply Wall St


Q1 numbers of Wockhardt delivered; MD Murtaza Khokriwala speaks to ET Now - Times Now


Cipla Rumored Frontrunner For Wockhardt Deal :: Generics Bulletin - Generics Bulletin


What Kind Of Shareholder Appears On The Wockhardt Limited's (NSE:WOCKPHARMA) Shareholder Register? - Simply Wall St


Is Wockhardt Limited (NSE:WOCKPHARMA) On The Right Side Of Disruption? - Simply Wall St


WHO, vaccine makers discuss fast-tracking of vax rollout in Southeast Asia - Business Standard


Wockhardt gets DCGI nod for two novel antibiotic drugs - BusinessLine


Investors Who Bought Wockhardt (NSE:WOCKPHARMA) Shares Five Years Ago Are Now Down 76% - Simply Wall St


Principles Of Passing Off In Trademarks: Wockhardt Limited Vs. Torrent Pharmaceuticals Ltd. - Intellectual Property - India - Mondaq News Alerts


Catchup Capsule: Key APAC Insights You Need To Read - Pink Sheet


US FDA nod may give Pfizer’s approval case in India a boost - Hindustan Times


Coronavirus | India’s COVID cases drop to lowest in over 100 days - The Hindu


Health Check: How Prudently Does Wockhardt (NSE:WOCKPHARMA) Use Debt? - Simply Wall St


Is Dexamethasone The Next Hydroxychloroquine For India? - Generics Bulletin


The Delhi High Court allows use of Anaday against Amaday - Lexology


Why now is the right time to invest in Mexican pharma - MercoPress


Volatility 101: Should Wockhardt Shares Have Dropped 50%? - Simply Wall St


Glucose Sensors Market 2020-2026 to Showcase Continued Growth | Major Players – Novo Nordisk A/S, Nipro, InjexUK, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Ypsomed – The Courier - The Courier


Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China - Scrip


WHO prequalifies BE's Typhoid Conjugate Vaccine - Business Insider India


Outlook on the Biosimilars Global Market to 2026 - Patent Expirations of Major Biologics Leads Way for Biosimilars - GlobeNewswire


Human Insulin Market Size 2021 Analysis, Growth, Vendors, Drivers, Challenges With Forecast To 2027 – NeighborWebSJ - NeighborWebSJ


Wockhardt receives ANDA approval for pain medication Oxycodone liquid - PR Newswire


AstraZeneca will test Sputnik V component in clinical trials of its own vaccine - Business Insider India


India Q2 Preview: Glenmark, Cipla Emerge Stronger - Scrip


Wockhardt receives USFDA warning letter to Morton Grove Pharmaceuticals Inc's facility - Equity Bulls


Wockhardt Hospitals Links With IndUShealth To Provide Treatments In India For American Patients - PR Web (press release)


Worldwide Biosimilars Industry to 2026 - Key Players Include Amgen, AXXO and Biogen Among Others - PRNewswire


Pharmaceutical Fill and Finish Outsourcing Market Outlook 2026: Market Trends, Segmentation, Market Growth and Competitive Landscape with key players position (Abbott Laboratories, Teva Pharmaceuticals Industries Ltd, Piramal Enterprises Ltd., Dr. Reddys Laboratories Ltd. and others) - The Bisouv Network


Wockhardt’s Director Huzaifa Khorakiwala To Launch Angel Fund – Targets $19 Mn For Healthcare ... - Inc42 Magazine


NPPA fixes retail price of 26 formulations; Details - Medical Dialogues


Pharma companies guilty of overcharging to get one-time interest waiver of Rs 1,325 crore - Business Today


Cempra makes CEO change ahead of FDA decision - BioPharma Dive


Nobel Peace laureate Kailash Satyarthi Facilitated with Lifetime Achievement Award - Outlook India


7 Indian drug makers named in US lawsuit for inflating prices of generic medicines - Business Today


Joy to the World — Founding Father of Indian Company with Mission for Health - Capital Finance International


A Decade's Deals In Indian Pharma Point To 2020 Trends - Scrip


Human Insulin Drugs & Delivery Devices Market Research Report by Product, by Distribution Channel, by Application, by Vendor Type, by User – Global Forecast to 2025 – Cumulative Impact of COVID-19 – SoccerNurds - SoccerNurds


In review: court procedure in India - Lexology


Delhi High Court sets aside notification banning a fdc and remands the matter to dtab/sub-committee constituted by dtab - Lexology


Biosimilars Market, 2025 - Company Profiles of 40+ Major Players & Industry Guide with Contact Details for 150+ Companies - GlobeNewswire


Stocks in the news: ZEEL, CDSL, SBI, Granules India, Cipla and DHFL - Economic Times


Wockhardt Foundation signs MOU with Wasan Knowledge Hub - IndiaCSR


Abbott Readying Vildagliptin ER In India Amid Price Competition - Scrip


Wockhardt stock closes 9.02% higher even as Q2 net loss widens to Rs 23 crore - Business Today


India's Data Integrity Problems | RAPS - Regulatory Focus - Regulatory Focus


Sir Dr. Huz to give leadership talk at CG CSR Leadership Summit at Raipur on 6 Feb - IndiaCSR


J&J, Pfizer, Russian COVID-19 Vaccines Set For Indian Approval In '21 - Scrip


Class-action lawsuits against Indian pharma companies on the rise - Business Standard


ALB India Law Awards 2020 | Asian Legal Business - Legal Business Online


Global Biosimilars Market to 2025 - mAbs, All The Rage In Biosimilars' New Wave - PRNewswire


Overnight Digest: Stocks to look out on August 26 - Dalal Street Investment Journal

Overnight Digest: Stocks to look out on August 26  Dalal Street Investment Journal


Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos - Scrip


Aspire Cerebro appoints Sanjeev Chopra as CEO of its India business - Exchange4Media


Research and Markets: Haemophilus Influenzae Infections - Pipeline Review, H2 2013 - Business Wire


India competition report - Lexology


Pharmaceutical trademark case law analysis - Lexology


Davinder Singh Brar Elected As Chairman of Mphasis Board - BW Businessworld


Happy is the new rich! - thecsrjournal

Happy is the new rich!  thecsrjournal


NPPA fixes retail price of 59 combo drug formulations including Paracetamol, Metformin, Atorvastatin;... - Medical Dialogues


Company Details

CIN.

L24230MH1999PLC120720

ROC Code

RoC-Mumbai

Date of Incorporation

08/07/1999

D&B D-U-N-S® Number

65-XXX-9115


Company Category

Company limited by Shares

Company SubCategory

Non-govt company

Class of Company

Public

Industry

MANUFACTURING


Authorised Capital( INR)

11,250,000,000

Paid up Capital( INR)

3,853,525,015

Number of Members

0

Registered Address

WOCKHARDT RESEARCH CENTRE, D-4, M.I.D.C. CHIKALTHANA AURANGABAD Aurangabad MH 431006 IN


Email Id

narendras@wockhardt.com

Whether Listed or not

Listed

Last AGM

04/08/2018

Last Balance Sheet

31/03/2018


Registration Number

120720

Location

Potentially Related Company Based on Common Directorship

Company Name Common Directors
WOCKHARDT HOSPITALS LIMITED 4
KHORAKIWALA FOUNDATION 3
KHORAKIWALA HOLDINGS AND INVESTMENTS PRIVATE LIMITED 2
DENARIUS ESTATE DEVELOPMENT PRIVATE LIMITED 2
HELIKE TRADING & SERVICES LLP 2
HNZ TRADING & SERVICES LLP 2
HZ TRADING & SERVICES LLP 2
AMADOU ESTATE DEVELOPMENT PRIVATE LIMITED 2
AMALTHEA TRADING & SERVICES LLP 2
ADRASTEA TRADING & SERVICES LLP 2
DARTMOUR HOLDINGS PRIVATE LIMITED 2
GENISTA TRADING AND SERVICES PRIVATE LIMITED 2
SHRAVAN CONSTRUCTIONS PRIVATE LIMITED 2
LYSITHEA TRADING & SERVICES LLP 2
MERIND LIMITED 2
PALANPUR HOLDINGS AND INVESTMENTS PRIVATE LTD 2
WOCKHARDT MAHARASHTRA HOSPITAL LIMITED 2
WYETH LEDERLE (EXPORTS) LIMITED 1
ZAPPA JOBS & SOLUTIONS PRIVATE LIMITED 1
ZI SPAS AND WELLNESS PRIVATE LIMITED 1
PARAMPARA FAMILY BUSINESS INSTITUTE 1
PASITHEE TRUSTEE COMPANY PRIVATE LIMITED 1
PEACE CAFEE WELFARE FOUNDATION 1
PROHEALTH CATALYSTS PRIVATE LIMITED 1
RPG LIFE SCIENCES LIMITED 1
MOUNTAIN TRAIL FOODS PRIVATE LIMITED 1
MPHASIS LIMITED 1
OOF VENTURES PRIVATE LIMITED 1
MADHUBANI INVESTMENTS PRIVATE LIMITED 1
MARUTI SUZUKI INDIA LIMITED 1
MAX FINANCIAL SERVICES LIMITED 1
MEGACLITE TRADING PRIVATE LIMITED 1
SINOPE ADVISORY SERVICES PRIVATE LIMITED 1
STEP FORWARD ADVISORY SERVICES PRIVATE LIMITED 1
SURAJ HOTELS PRIVATE LIMITED 1
SURAJ OVERSEAS PRIVATE LIMITED 1
TATA MOTORS FINANCE SOLUTIONS LIMITED 1
TATA MOTORS LIMITED 1
TATA STEEL LIMITED 1
THE BOMBAY DYEING AND MANUFACTURING COMPANY LIMITED 1
THE PEACE MISSION PRIVATE LIMITED 1
THEMISTO TRUSTEE COMPANY PRIVATE LIMITED 1
TMA ESTATES LLP 1
TML DISTRIBUTION COMPANY LIMITED 1
VEDANTA LIMITED 1
VINTON HEALTHCARE LIMITED 1
WOCKHARDT BIOPHARM LIMITED 1
GO AIRLINES (INDIA) LIMITED 1
GODREJ CONSUMER PRODUCTS LIMITED 1
GREEN VALLY LAND AND DEVELOPMENT PRIVATE LIMITED 1
GVK BIOSCIENCES PRIVATE LIMITED 1
GVK DAVIX RESEARCH PRIVATE LIMITED 1
GVK DAVIX TECHNOLOGIES PRIVATE LIMITED 1
DAVIX MANAGAEMENT SERVICES PRIVATE LIMITED 1
DAVIX PHARMACEUTICALS PRIVATE LIMITED 1
ADVENT GLOBAL SOLUTIONS PRIVATE LIMITED 1
AGAPPE DIAGNOSTICS LIMITED 1
ANANKE TRUSTEE COMPANY PRIVATE LIMITED 1
ARTEMIS GLOBAL LIFE SCIENCES LIMITED 1
ARTEMIS MEDICARE SERVICES LIMITED 1
ATUL LIMITED 1
BOMBAY BURMAH TRADING CORPORATION LIMITED 1
CAIRN INDIA LIMITED 1
CALLIRHOE TRUSTEE COMPANY PRIVATE LIMITED 1
CONCORDE MOTORS (INDIA) LIMITED 1
CSR ADVISORS PRIVATE LIMITED 1
I AM PEACEKEEPER ENTERPRISES PRIVATE LIMITED 1
I AM VEG ENTERPRISES PRIVATE LIMITED 1
IMPALA ADVISORY SERVICES PRIVATE LIMITED 1
INOGENT LABORATORIES PRIVATE LIMITED 1
INSPIRATION CAFEE PRIVATE LIMITED 1
INTERNATIONAL INSTITUTE OF CSR FOUNDATION 1
INVEST INDIA 1
KENDO ADVISORY SERVICES PRIVATE LIMITED 1
HELP ME SERVE PRIVATE LIMITED 1
DR.HABIL KHORAKIWALA EDUCATION AND HEALTH FOUNDATION 1
EXCELRA KNOWLEDGE SOLUTIONS PRIVATE LIMITED 1
KIRLOSKAR INDUSTRIES LIMITED 1
KIRLOSKAR OIL ENGINES LIMITED 1
LIVE 24 COMMUNICATIONS PRIVATE LIMITED 1
WOCKHARDT INFRASTRUCTURE DEVELOPMENT LIMITED 1
7 PEACE VALUES PRIVATE LIMITED 1

Charges

Charge Holder Name Assets under charge Charge Amount Date of Creation Date of Modification Status
SBICAP TRUSTEE COMPANY LIMITED Movable property (not being pledge); Please refer attached DOH dated 19th October, 2016 16,745,325,000 31/08/2016 19/10/2016 OPEN
ING VYSYA BANK LIMITED Movable property (not being pledge) 1,341,400,000 23/11/2009 - CLOSED
IDBI Bank Limited Movable property (not being pledge) 1,679,000,000 23/11/2009 - CLOSED
THE FEDERAL BANK LTD Movable property (not being pledge) 150,000,000 23/11/2009 - CLOSED
EXPORT IMPORT BANK OF INDIA Movable property (not being pledge) 150,000,000 31/05/2000 - CLOSED
ICICI BANK LIMITED Movable property (not being pledge) 2,990,100,000 23/11/2009 - CLOSED
Indian Overseas Bank Movable property (not being pledge) 293,100,000 23/11/2009 - CLOSED
STATE BANK OF INDIA Movable property (not being pledge) 3,820,000,000 23/11/2009 - CLOSED
ICICI LTD Movable property (not being pledge) 300,000,000 27/06/2000 - CLOSED
SBICAP TRUSTEE COMPANY LIMITED Movable property (not being pledge) 4,667,210,000 29/06/2010 - CLOSED
PUNJAB NATIONAL BANK Movable property (not being pledge) 450,000,000 25/03/2009 - CLOSED
HDFC BANK LIMITED Movable property (not being pledge) 484,900,000 23/11/2009 - CLOSED
THE BANK OF NOVA SCOTIA Movable property (not being pledge) 500,000,000 23/11/2009 - CLOSED
ICICI BANK LIMITED Movable property (not being pledge) 550,000,000 24/03/2009 - CLOSED
ICICI BANK LIMITED Movable property (not being pledge) 700,000,000 14/04/2009 - CLOSED
PUNJAB NATIONAL BANK Movable property (not being pledge) 843,200,000 23/11/2009 - CLOSED
STATE BANK OF INDIA Movable property (not being pledge) 878,600,000 24/06/2004 - CLOSED
BANK OF INDIA Movable property (not being pledge) 956,100,000 23/11/2009 - CLOSED
HSBC BANK PLC Movable property (not being pledge) 987,800,000 19/02/2009 - CLOSED
SBICAP TRUSTEE COMPANY LIMITED Motor Vehicle (Hypothecation); Movable property (not being pledge); as per sch III of attached Deed of Hypothecation 2,000,000,000 15/02/2019 27/02/2019 OPEN
SBICAP TRUSTEE COMPANY LIMITED Immovable property or any interest therein; Movable property (not being pledge); No change in the security 11,250,500,000 27/01/2016 18/06/2018 OPEN
STATE BANK OF INDIA Immovable property or any interest therein; Movable property (not being pledge) 1,805,000,000 21/04/2009 - CLOSED
STATE BANK OF INDIA Immovable property or any interest therein; Movable property (not being pledge) 1,805,000,000 21/04/2009 - CLOSED
STATE BANK OF INDIA Immovable property or any interest therein; Movable property (not being pledge) 550,000,000 10/12/2008 - CLOSED
SBICAP TRUSTEE COMPANY LIMITED Immovable property or any interest therein; current assets of the Company 2,575,000,000 18/08/2010 06/04/2017 CLOSED
STATE BANK OF INDIA Immovable property or any interest therein; Book debts; Movable property (not being pledge) 11,250,000,000 08/02/2007 - CLOSED
SBICAP TRUSTEE COMPANY LIMITED Immovable property or any interest therein; As detailed in the letter issued by SBICTCL 2,500,000,000 31/12/2015 10/10/2016 OPEN
SBICAP TRUSTEE COMPANY LIMITED Immovable property or any interest therein 2,000,000,000 23/03/2009 06/05/2013 CLOSED
SBICAP TRUSTEE COMPANY LIMITED Immovable property or any interest therein 2,575,000,000 31/08/2010 22/12/2016 CLOSED
SBICAP TRUSTEE COMPANY LIMITED Immovable property or any interest therein 2,575,000,000 31/08/2010 22/12/2016 CLOSED
IDBI Bank Limited Immovable property or any interest therein 500,000,000 21/05/2009 - CLOSED
STATE BANK OF INDIA Immovable property or any interest therein 687,300,000 24/06/2004 20/08/2008 CLOSED
State Bank of India Book debts; Movable property (not being pledge) 1,139,280,000 29/12/2000 12/04/2019 OPEN
SBICAP TRUSTEE COMPANY LIMITED Book debts; Movable property (not being pledge) 2,500,000,000 11/06/2015 - CLOSED
State Bank of India Book debts; Movable property (not being pledge) 3,625,000,000 09/12/2002 12/04/2019 OPEN
BANK OF INDIA Book debts; Movable property (not being pledge) 600,000,000 06/10/2008 - CLOSED
ICICI BANK LIMITED Book debts; Floating charge; Movable property (not being pledge) 675,000,000 11/04/2009 - CLOSED
State Bank of India Book debts 1,033,200,000 03/01/2000 - CLOSED
ABN AMRO BANK Book debts 155,000,000 12/10/2004 - CLOSED
IDBI Bank Limited 1,000,000,000 08/09/2008 21/05/2009 CLOSED
SBICAP TRUSTEE COMPANY LIMITED 2,500,000,000 01/07/2015 08/01/2016 OPEN
DEPARTMENT OF BIOTECHNOLOGY 26,152,000 16/11/2010 07/12/2011 CLOSED
SBICAP TRUSTEE COMPANY LIMITED 3,570,000,000 21/07/2010 23/02/2016 CLOSED
SBICAP TRUSTEE COMPANY LIMITED 3,570,000,000 21/08/2010 23/02/2016 CLOSED
IDBI Bank Limited 500,000,000 18/03/2009 21/05/2009 CLOSED
SBICAP TRUSTEE COMPANY LIMITED 6,250,000,000 30/03/2015 08/01/2016 OPEN

Principals/Signatory Details

Identification Number Principal Names Designation Begin date End date
00009364 AMAN MEHTA Director 12/02/2004 -
00045608 HABIL FAKHRUDDIN KHORAKIWALA Wholetime Director 08/07/1999 -
00068502 DAVINDER SINGH BRAR Director 06/08/2012 -
00102650 MURTAZA HABIL KHORAKIWALA Managing Director 29/06/2009 -
00102689 ZAHABIYA HABIL KHORAKIWALA Director 30/10/2017 -
00194168 BALDEV RAJ ARORA Director 28/05/2015 -
00391684 VINESH KUMAR JAIRATH Director 10/11/2016 -
00444343 RIMA NAYAN MARPHATIA Nominee Director 06/05/2019 -
02191870 HUZAIFA HABIL KHORAKIWALA Wholetime Director 29/06/2009 -
05009664 TASNEEM VIKRAM SINGH MEHTA Director 30/09/2014 -
05344208 SANJAYA BARU Director 06/08/2012 -
XXXXXXXXXX MANAS KUMAR DATTA CFO(KMP) 10/09/2014 -
XXXXXXXXXX NARENDRA SINGH Company Secretary 28/05/2015 -

Corporate Family Connections

Detailed profiles of all businesses owned and operated by this company for insights and prospecting.

31 Subsidiaries


0 Branches


0 Affiliates

Company network based on common directorship

© 2021 - Dun & Bradstreet Information Services India Pvt Ltd. All rights reserved.